ArticleInfectious diseases and therapy2026

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study.

Benjamin Yarnoff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.